KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 1 Not yet finished but already full! 3 Completed 1

New pill targets tough cancers: early trial shows promise

Disease control Completed

This study tested an oral drug called GFH925 in 334 people with advanced solid tumors that have a specific KRAS G12C mutation. The trial aimed to find the safest dose and check if the drug can shrink tumors in cancers like lung and colorectal cancer. Results will help decide if l…

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control

Last updated Jun 27, 2026 07:57 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New pill targets tough cancers: early trial shows promise